Covid hospitalisations are at the ‘highest level’ of 2025. Cases of the newest Covid variant LP.8.1 are on the rise. LP.8.1 was first detected in July 2024 and originates from the Omicron variant. The ...

The newest Covid variant LP.8.1 now accounts for more than 30% of cases 🤧 There have been many different Covid variants since the Covid pandemic in 2020. LP.8.1 was first detected in July 2024 and ...

Findings from this trial reinforce the preclinical data supporting the approval of the LP.8.1-adapted COVID-19 vaccine for the 2025-2026 season. Topline results were announced from a phase 3 trial ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Adrian Esterman receives funding from the NHMRC, MRFF and ARC. COVID rarely rates a mention in the news these days, yet it hasn’t gone away. SARS-CoV-2, the virus that causes COVID, is still with us.

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...